Hepatitis B in the Northwestern region of Sao Paulo State: genotypes and resistance mutations.
PMID: 34755817
2021
Revista do Instituto de Medicina Tropical de Sao Paulo
Result: In the group of patients undergoing treatment, strains of HBV with resistance mutations (rtM204V/I/S) associated or not with compensatory mutations (rtL180M, rtV173L) were identified in 13.9% (5/36) of the analyzed samples.
Result: Strains with partial resistance mutations for ETV (rtM204V/I/S) or potentially associated with resistance to ADF (rtV214A, rtL217R, rtQ215S, rtN238T, and
Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: In fact, a systematic review by Zhang et al revealed that the global incidence of rtM204I/V/S is 4.85%.
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Result: No mutations known to cause tenofovir resistance (L180M, A181I/V, A194T, M204V/I, V214A, Q215S, N236T) or lamuvudine (3TC) resistance (L80V/I, I169T, V173L, L180M, A181T, T184S, M204V/I/S, Q215S) were observed.
Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
PMID: 31189581
2019
Journal of clinical microbiology
Result: Considering that the low sensitivity of Sanger sequencing limited the detection of NAr mutations with a low rate (<20%), 4 classical drug resistance mutations (S202C/G/I, M204I/V/S, N236T, and M250I/L/V) and 12 putative NAr mutations (V207I, S213T, V214A, Q215P/S, L217R, E218D, L229G/V/W/F, I233V, P237H, N/H238D/S/T, Y245H, and S/C256G)
[Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Method: A systematic review by Zhang et al revealed that the global incidence of rtM204I/V/S is 4.85%.
Method: For examples, Kobayashi et al, Lee et al, Tuncbilek et al, Fung et al, and Huang et al reported rtM204I/V/S mutation frequencies in Japanese, Taiwanese, Turkish, Canadian, and Chinese treatment-naive patients reached of 27.8%, 57%, 7.8%, 12%, and 26.9%, respectively.
Method: Several other studies have also reported the frequent incidence of rtM204I/V/S in treatment-naive patients.
Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Method: As previously described, we used the Mutation Reporter Tool (MRT) software (http://hvdr.bioinf.wits.ac.za/mrt/) to look for HBV resistance-associated mutations (RAMs) in the Polymerase catalytic domain represented by major RAMs (A181T/V/S, A194T, M204V/I/S and N236T) and compensatory RAMs (I169T, V173L, L180M, S202G/I and M250V.
The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.
Abstract: RESULTS: A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group.
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.
PMID: 27313669
2016
Experimental and therapeutic medicine
Introduction: These resistant variants include rtM204V, rtM204I and the infrequently identified rtM204S.
HBV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT